Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06039280 |
Recruitment Status :
Not yet recruiting
First Posted : September 15, 2023
Last Update Posted : September 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Carcinoma | Drug: N Acetylcysteine Drug: Dexamethasone Other: Placebo | Not Applicable |
Aim & Objectives Hypothesis: The combination of dexamethasone with NAC is superior to NAC alone in prevention of PES among patients who undergo TACE in HCC as both medications work differently to prevent PES.
AIM:- To study the efficacy of combining Dexamethasone to N acetyl cysteine in prevention of post embolization syndrome within 72 hours among patients who undergo transarterial chemoembolization for HCC.
Objective - PRIMARY Prevention of post embolisation syndrome within 72 hours.
SECONDARY
- Prevention of post embolisation decompensation at 2 weeks.
- Decrease in the duration of hospitalization.
- To study the adverse effects of NAC and steroids in patients who undergo transarterial chemoembolisation for HCC.
Methodology:
Study population:
- All patients undergoing TACE procedure
- Valid Consent
- Age 18-65 years
Study design:
Monocentric open label prospective randomized controlled study. The study will be conducted in Department of Hepatology, ILBS.
Sample size:
- Assuming that NAC prevents PES by 75% and addition of dexamethasone further prevents PES by 20 % (i.e combination of NAC and Dexamethasone prevents total 95%).
- Then with alpha as 5% and power 90 % .we need to enroll total 130 cases i.e 65 in each arm.
- Further assuming 10% drop out , it is decided to enroll 150 cases i.e. 75 in each arm.
- Allocation will be done randomly by block randomization method, taking block size as 10.
Monitoring and assessment: All the parameters of the objective and also noted any adverse effects.
Intervention: TACE.
STATISTICAL ANALYSIS:
The data will be entered in Microsoft excel and will be analyzed using SPSS version 22. The categorical data will be analyzed using Chi square/Fissure test. Exact test and continuous data will be compiled using t-test. Besides this the univariate and multivariate survival analysis will be carried out using Cox regression method. Kaplan-Meier technique will be applied for further analysis. P-value<0.05 will be considered as significant.
Adverse effects: allergic drug reaction.
Stopping rule: If patient decided to withdraw from study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization - Randomized Controlled Trial. |
Estimated Study Start Date : | September 15, 2023 |
Estimated Primary Completion Date : | July 31, 2024 |
Estimated Study Completion Date : | July 31, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: NAC+Dexamethasone
NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure. Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure. |
Drug: N Acetylcysteine
NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure. Drug: Dexamethasone Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure. |
Active Comparator: NAC+Placebo
NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
|
Drug: N Acetylcysteine
NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure. Other: Placebo The placebo will be administered in the same way as the drug in the experimental group. |
- Prevention of post-embolization syndrome [ Time Frame: 72 hours ]Prevention of Post-embolization syndrome , Defined base on South west oncology group (SWOG) toxic coding less than 2 score
- Prevention of post TACE decompensation at 4 weeks [ Time Frame: 4 weeks ]Metric / Method of measurement : Post TACE decompensation defined as an increase in Child-Pugh score of more than two points or newly developed decompensating events, such as ascites, hepatic encephalopathy, or serum total bilirubin > 2 mg/dL.
- Decrease in the duration of hospitalisation [ Time Frame: 4 weeks ]
- Adverse events of Dexamethasone and NAC in patients undergoing transarterial chemoembolisation for HCC [ Time Frame: 2 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients undergoing TACE procedure
- Valid Consent
- Age 18-65 years
Exclusion Criteria:
- Child Pugh C, Child Pugh B > 8
- HCC patients with a curative therapy (Ablation, Resection or LT)
- ECOG Performance Status 3-4
- Pregnancy
- History of allergic reaction from NAC
- significant cardiopulmonary disease
- UGI bleed within last 28 days
- Recent surgery within last 28 days
- Documented febrile illness in last 1 weeks
- Uncontrolled Diabetes (FBS > 200, HBA1C > 8)
- Uncontrolled Hypertension (BP > 160/100)
- Structural kidney disease with eGFR < 60 ml/min
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06039280
Contact: Dr Phool Chand, MD | 01146300000 | phoolchand99@gmail.com |
India | |
Institute of Liver & Biliary Sciences | |
New Delhi, Delhi, India, 110070 | |
Contact: Dr Phool Chand, MD 01146300000 phoolchand99@gmail.com |
Responsible Party: | Institute of Liver and Biliary Sciences, India |
ClinicalTrials.gov Identifier: | NCT06039280 |
Other Study ID Numbers: |
ILBS-HCC-06 |
First Posted: | September 15, 2023 Key Record Dates |
Last Update Posted: | September 15, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Acetylcysteine Dexamethasone N-monoacetylcystine Anti-Inflammatory Agents |
Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers |